Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NIPTNIxHfW6ldHnvckBCe3OjeR?= M{\WRlAvP87:TR?= MVOyOIg> MWHleIhidm:u MVflcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm Mn;sNlU4QDdyN{m=
TE13 NX3TWndsTnWwY4Tpc44hSXO|YYm= NXrSe3pUOC5|zszN NEXmRZYzPGh? MXT1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NVHq[HdjOjV3N{m2OlU>
TE13 NV\pTG5bSXCxcITvd4l{KEG|c3H5 MUewMlPPxE1? MoruNlRp MYLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v M1XBcVI2PTd7Nk[1
MEFs NUDBfZFSTnWwY4Tpc44hSXO|YYm= NYO1WpBtPc7:TR?= MUGxOog> NWD6bm82cW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w Mo\UNlU1QDJ4M{S=
SW480  NVTmTHQyTnWwY4Tpc44hSXO|YYm= NWfxdJY2OC5zzszN NU\keVZxPDiq M1LHbmROW09? M3P3XpJmfmW{c3XzJGVOXA>? MYWyOVQ{PDl7Nx?=
PC3  NXrre2pyTnWwY4Tpc44hSXO|YYm= Mlj4NE4y|ryP MVe0PIg> MWHEUXNQ M3GzPZJmfmW{c3XzJGVOXA>? NXrlSmJROjV2M{S5PVc>
SW480  NIjSOZZHfW6ldHnvckBCe3OjeR?= NYXhTlQ5OC5zzszN NIjyS3U1QGh? NX\nXW5kTE2VTx?= MYrheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? NEHuT5UzPTR|NEm5Oy=>
PC3  M4nHUmZ2dmO2aX;uJGF{e2G7 MmmxNE4y|ryP MVe0PIg> M3mwRWROW09? MlG5ZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MVeyOVQ{PDl7Nx?=
SW480  NFPjVIhHfW6ldHnvckBCe3OjeR?= M2LVRlAvOc7:TR?= NXPvN|dnPDiq M134OGROW09? MWrpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M2n0OFI2PDN2OUm3
PC3  MnK5SpVv[3Srb36gRZN{[Xl? NGLte3IxNjIQvF2= NGTuNIw1QGh? NIe5PJBFVVOR NXfpUm85cW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= Mmj5NlU1OzR7OUe=
A431 M1u4[GFxd3C2b4Ppd{BCe3OjeR?= MlnNNk8yOC93MD:xNFBvVQ>? M4n0NFQ5cA>? MlnISG1UVw>? NXHDe4dZcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To NILQUnozPTN5MUC2PS=>
A431 MmOzSpVv[3Srb36gRZN{[Xl? M4C5d|Uxdk1? NFnKW4IzNzZxMUKvNlRp MYjEUXNQ M2n1cIFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= Mk\5NlU{PzFyNkm=
MDA-MB-231 M1vOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\h[nI5OC14MEDuUS=> MoG2NlRp NYSxW2U4TE2VTx?= NFvxd|RKSzVyIH;mJFExOG6P MmW4NlUyQTJ5MkG=
MCF7 NF64eFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjpblYxNTZyMH7N MV[yOIg> NWLjUHJbTE2VTx?= M2nNPWlEPTBib3[gO|VvVQ>? M4KzOVI2OTl{N{Kx
SKOV-3 NWmwWmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX1NU0yOM7:TR?= MX6yOIg> MW\EUXNQ NV21dpJGUUN3MDDv[kA2NjcQvF2= MmPBNlUyPjl2OUG=
A549 M4Swc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPzNU0yOM7:TR?= MYWyOIg> M2jXdGROW09? M2e5XGlEPTBib3[gN{4z|ryP Mo\qNlUyPjl2OUG=
SKOV-3 NVuwZpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTzNE4yNTIQvF2= NWTVT|N[PDiq MXrEUXNQ M3L4N2lEPTBib3[gNE44|ryP MknPNlUyPjl2OUG=
A549 NGiwOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jWIx1OC5zLUJOwG0> NXTveFJkPDiq MnjDSG1UVw>? NX\hSFYyUUN3MDDv[kAxNjJ6zszN NEP3dW0zPTF4OUS5NS=>
SKOV-3 NEn6S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\n[4pkOC5yMT2wMlnPxE1? MUi3Nog> M3\qcmROW09? MVXJR|UxKG:oIECuN|LPxE1? NHPqTGczPTF4OUS5NS=>
A549 NXj1U2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor0NE4xOS1yLkpOwG0> MlPqO|Jp NFzrcVlFVVOR NIKwU4VKSzVyIH;mJFAvODcQvF2= M1fiWlI2OTZ7NEmx
HeLa NFvKdIVHfW6ldHnvckBCe3OjeR?= MYSyOVBvVQ>? MVKxOog> MmKySG1UVw>? NUTEVHFrcW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> M4HVb|I2OTF4Nki4
CNE2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDENIZLOTByLU[wNI5O M1PJfVI1NzR6L{eybC=> MXHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUPld|ZmOjR7Nkm5NFE>
PC3 NXq5flVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3WdXQyODBvMUCwNI5O M373UlI1cA>? MkT4TWM2OCCxZjCzNFBvVQ>? MYiyOFg2PDZ3OB?=
LNCaP M4jufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNFAuOTByMH7N MomzNlRp NYLOTohpUUN3MDDv[kA{ODCwTR?= MlnTNlQ5PTR4NUi=
HeLa  MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PCcFLPxE1? NVfqfVNyPDiq M33TeoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NHLEVHQzPDh2NkGzOS=>
HMEC-1  NGHDSIJHfW6ldHnvckBCe3OjeR?= NWXN[FBjOzBybl2= NYGxUnd6OjSq MV7pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B NWiwcIw2OjR5MUC2N|E>
HeLa NXHLOGhETnWwY4Tpc44hSXO|YYm= NYDlWGR[OW2P MVSwMlVp NFKwS2Ji[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= MUGyOFcxPzR5NB?=
ACP02 NV\6UGY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUeyOVAwOzVyL{WwNI5O MV:yOIg> NUfNTIdG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= M4X6[FI1PjZ6NUS3
ACP03 NF;PPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK1Sm0zPTBxM{WwM|UxOG6P NXSzfGxJOjSq NHPpZ4Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P NWXVdlJDOjR4Nki1OFc>
U87 GBM MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfHNWJiOTByL{OwNE82ODBibl2= MVS3NkBp NXP2cJc5OTByJTDleIhidm:u MVzy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= NGWxSXczPDR4NEi0NS=>
U87 GBM NV\zfJl5TnWwY4Tpc44hSXO|YYm= M3L6OFExOC93MECgUo0> MorKOFghcA>? MkXtNVAxLSCndHjhco9t NELYb4RKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? MkDhNlQ1PjR6NEG=
RPE M{\4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3vSJMxNjJxMD60M|AvQC9zIN88US=> M3n0[|I1NzR6L{eyJIg> NHf0Z49FVVOR MXzpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDifUBk\WyuIHP5Z4xmKGG{cnXzeC=> NXPjcog1OjR2NU[2NFI>
HT29  MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDONmc3OThyIH7N MVu3NkBp M{naTGlEPTBib3[gNVgxKG6P NV3XN4RiOjR|NkiyOlU>
hMSCs NIL3W2lHfW6ldHnvckBCe3OjeR?= NW\6O3VXPi5{NTDuUS=> MX:yOEBp MXrEUXNQ NI\PPZN{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz NUn6TZZCOjR|MUKzOVY>
Huh7  MYnGeY5kfGmxbjDBd5NigQ>? NH\sRVMxNjFxMD61M|EvOCEQvF2= NVm1NINNOjSq NX23UpNye3WycILld5NmeyC\VFjER|Ih\2WwZTDlfJBz\XO|aX;u NV35c4cyOjR{Nkm2O|I>
SKOV3 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XUbVAvODVvMjFOwG0> NHLlVGkyOC9{ND:0PEBp M2XlPWROW09? NHfZ[HJu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NInuXmczPDJ{M{iwNS=>
A2780 NFm3fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTqNE4xPS1{IN88US=> M{WxNFExNzJ2L{S4JIg> NYPWU4pnTE2VTx?= NX\UdpZydWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M4TrTVI1OjJ|OECx
SRA01/04  NV;M[ol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlIh|ryP NGCx[JY1QCCq NIfqOplFVVOR M4jlXZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MV[yOFE2Pzh5OB?=
HLEB3 NHz6SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPhemw1OC5{IN88US=> MXK0PEBp NFPzcllFVVOR NWHNdIRie3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? NE\5[IEzPDF3N{i3PC=>
SRA01/04  NWDlWmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\YRVAvPC9yLkig{txO M4rWU|Q5KGh? NYS2U4Q5TE2VTx?= MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYHaNVJuOjRzNUe4O|g>
HLEB3 NF\jVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTtNE41NzBwODFOwG0> M4PGWlQ5KGh? M{nsTWROW09? NVy3SHU6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGi0O24zPDF3N{i3PC=>
HCT116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMlIh|ryP M2f6ZlEzKGh? NWKxXYJP\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> MVeyOFEzOjJ|MR?=
CA46 M1O5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6zM|YwOTJxMkSvOFghdk1? MnXXOFghcA>? NHO1PVRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi MWqyOFA3PDl3MR?=
PMNs NYLZSGs2TnWwY4Tpc44hSXO|YYm= NVXQdZQ6OzBibl2= NGLSUmM1QCCq M2Xrc4lvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> M1vxWVI{QTh6NkG3
H1299 M4HndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPrTpEzOcLizszNxsA> Mnf5NlQwPDhxN{KgbC=> NGPJNoZmfGijbn;s NFvjdY5qdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh? NVvJXJhUOjN7MU[2NFk>
A549 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrFNE4zPS9yLkWvNUDPxE1? M3qwU|I1NzR6L{eyJIg> M4rNXoV1cGGwb3y= MnnBbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MX[yN|g3Pzl7MR?=
H1299 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzZmtpOC5{NT:wMlUwOSEQvF2= MVeyOE81QC95MjDo NI\jXmJmfGijbn;s NG\wdHdqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NH;nN2YzOzh4N{m5NS=>
A549 MV7BdI9xfG:|aYOgRZN{[Xl? M2fLSFAvPS9zIN88US=> M2HpblQ5KGh? NIr3[mRmfGijbn;s MnPubY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mmr5NlM5Pjd7OUG=
H1299 MUTBdI9xfG:|aYOgRZN{[Xl? MoWyNE42NzFizszN Ml7IOFghcA>? MYHleIhidm:u NF2zS4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFTYU28zOzh4N{m5NS=>
SUM149PT MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGixUnEzNzdwNT:xNEDPxE1? MmTzOFghcA>? NFe5NZdFVVOR MkfvbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? NEDQOoszOzd7Mk[zPC=>
SUM190PT NES3cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW1NE8yODBxMkWwJI5O NEfJbJY1QCCq MmDmSG1UVw>? NGe3SYxqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? Mm\lNlM4QTJ4M{i=
HCT1 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNNE4zNzFwMD:1MlAh|ryP NFTHTmoyOi9{ND:zOk81QCCq NHjNXVNqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M1jFVVI{PzdyMECw
Lovo NV23OYNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzV|AvOi9zLkCvOU4xKM7:TR?= M{ewUVEzNzJ2L{O2M|Q5KGh? Mnz1bY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MoPONlM4PzByMEC=
AGS MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHzNE4xOTVvMTFOwG0> M3fXelczKGh? NHX1dohqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NF;zTHAzOzd2NUCyOC=>
Huh7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K4[lEh|ryP MkGwNlQhcA>? M3rFe2ROW09? NH\4XnVz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? M{TJcFI{PjR|OUOz
ECC1 NXXCUG5TTnWwY4Tpc44hSXO|YYm= M17xO|UxOCCwTR?= NH7zTmY2KGR? Mof4SG1UVw>? MkfObY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NYjPZlQ1OjN3M{C3Olk>
HEC1A NIrpU|JHfW6ldHnvckBCe3OjeR?= MXi1NFAhdk1? M2fEPFUh\A>? MWfEUXNQ M1S4folv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M13xdFI{PTNyN{[5
EN1 NYP2TZA4TnWwY4Tpc44hSXO|YYm= NHHxc|I2ODBibl2= NX;ZZndPPSCm M1i4[GROW09? MonVbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NGO1c|UzOzV|MEe2PS=>
MFE296 M2PTTmZ2dmO2aX;uJGF{e2G7 MmP3OVAxKG6P NWHJd2ptPSCm MkCzSG1UVw>? NXy4OFN7cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NIWzT5gzOzV|MEe2PS=>
HASMCs NHfTU2lHfW6ldHnvckBCe3OjeR?= NWP0PXgzOC13MECgcm0> NUP6SI1VPiCm MkDU[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> M165VFI{PTF6NE[3
U373 NIDSOnFHfW6ldHnvckBCe3OjeR?= MV2wMlI2NzBwNT:xJO69VQ>? NVXDOIV4OjRiaB?= NUXTSZZrcW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= Mn7nNlM1PzRzN{G=
ARN8  NE\BdJFHfW6ldHnvckBCe3OjeR?= MWWwMlA2NTJizszN NWrqV3ZrOjRiaB?= NGrmbGlz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? NH;o[IwzOzR5MEW0NC=>
MCF7 M1viSGZ2dmO2aX;uJGF{e2G7 NFnubZUxNjB3LUKg{txO MV2yOEBp Mn;ldoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> M2DOS|I{PDdyNUSw
H1299  MonDSpVv[3Srb36gRZN{[Xl? NHzORWMxNjN|4pETNeKhyrWP M1X4T|I1NzR6IHi= NHT4SHFFVVOR NVXvdHNYcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> NVHqZlIyOjN2NkG5O|U>
H1299 M2DEbmZ2dmO2aX;uJGF{e2G7 M2nJc|AvPSEQvF2= M2K1OFQ5KGh? M2\WemROW09? Mn72bY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> MVSyN|Q3OTl5NR?=
H1299 NVTCTJBVTnWwY4Tpc44hSXO|YYm= MYewMlUh|ryP MVm0PEBp M4HY[WROW09? M2XFbolvcGmkaYTzJJRp\SCrbo\hd4l3\W6nc4RCpEBkd22kaX7lJJdqfGhic3nsbYJqdmmw MXeyN|Q3OTl5NR?=
MG-63  NV72O2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzG[XRjOC5|IN88US=> NGjjXZMyOi17NjDo MkXMSG1UVw>? Mlz1bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NET4ZmkzOzR3MUixOy=>
LM8 NFG0e25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMlMh|ryP M1q4OVEzNTl4IHi= MUPEUXNQ MlnCbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= M1fRT|I{PDVzOEG3
K562 MV7GeY5kfGmxbjDBd5NigQ>? M{\oVFAvPSEQvF2= NHvtb|UzPCCq NXzm[IhD\XSqYX7vcC=> M1jUSYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MYmyN|Q{ODl3Nx?=
HEL MXfGeY5kfGmxbjDBd5NigQ>? MlnhNE42KM7:TR?= M2LtSVI1KGh? M4W2UIV1cGGwb3y= M1TjNoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MYCyN|Q{ODl3Nx?=
HL60 M3;iTGFxd3C2b4Ppd{BCe3OjeR?= M3vSSVEh|ryP MoTuNlQhcA>? MVzpcoR2[2W|wrDj[YxtKGSnYYTo MV6yN|QxODVzOR?=
KG1 M2TYTGFxd3C2b4Ppd{BCe3OjeR?= Mni0NUDPxE1? NIf0eIczPCCq M17iXIlv\HWlZYRCpINmdGxiZHXheIg> NUHFdGZ4OjN2MEC1NVk>
Kazumi Ml62RZBweHSxc3nzJGF{e2G7 MUGxJO69VQ>? M2rrXFI1KGh? MlHxbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MWmyN|QxODVzOR?=
K562 NU\qTmNXSXCxcITvd4l{KEG|c3H5 MUixJO69VQ>? NFnqTmYzPCCq Mkj6bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MWCyN|QxODVzOR?=
THP1 M3XER2Fxd3C2b4Ppd{BCe3OjeR?= NH[0ZpoyKM7:TR?= NIjNflIzPCCq M3Wy[4lv\HWlZYRCpINmdGxiZHXheIg> M{nvSVI{PDByNUG5
SH-SY5Y NYXqS5FVTnWwY4Tpc44hSXO|YYm= M1T0S|I2OCCwTR?= NH7ZUoYyPiCq M4rzWINp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= MYWyN|MzPjR{Mh?=
HEK293 M2rBbmZ2dmO2aX;uJGF{e2G7 MkCyNUDDvU4EoB?= Mn73NVghcMLi NYfjTYFIcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= NVzsblFpOjN{OES4OFg>
HTK MlnsSpVv[3Srb36gRZN{[Xl? NV7hSJBFPDByIH7N NF7zdXE4OiCq M2T4cIlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> M3raVVI{Ojh2MECy
HTK NYDTe4hqTnWwY4Tpc44hSXO|YYm= M4rCTFExOC16MEDuUS=> NETuXlI4OiCq M2\tcYJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NY\CV3NJOjN{OESwNFI>
Caco-2  M2PPPWZ2dmO2aX;uJGF{e2G7 NELlSGIyKML3TdMg NGi3e4czPCCq NVq2NI9Q\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u MnvaNlMyQTVyN{C=
HeLa NVLDdGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDNVAxKG6P M{\KUlI1KGh? MoL5SG1UVw>? MU\JR|UxKG:oIEGwNI5O NVfmV3h1OjNzNkW3OFg>
HeLa M2\LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[0NEBvVQ>? MnfwOFghcA>? M4HRVGROW09? NGP4UlZKSzVyIH;mJFQxdk1? MlvpNlMyPjV5NEi=
HeLa MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVixRYpSOjBibl2= M1rJeVczKGh? MlHnSG1UVw>? NYPJfJlvUUN3MDDv[kAzOG6P Mo\CNlMyPjV5NEi=
HeLa NEjNenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYcY8yOC9|MD:1NEBvVQ>? NH22XYQ4OiCq NWDtS3JpTE2VTx?= NVS0UoR6cW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NV3kZXppOjNzNkW3OFg>
MDA-MB-231 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmyOU01ODBibl2= NXzodWlQPDhiaB?= NILqPW5KSzVyIH;mJFI3Oy5{bl5CpC=> NVjsfYxyOjNyNUWxPVg>
MCF-7  Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT4NlUuPDByIH7N M2[zWlQ5KGh? MlrTTWM2OCCxZjCyNlAvPG6P M4r2clI{ODV3MUm4
ECC-1  Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPTFExOCCwTR?= NIHESVEzPCCq M3jreIV1cGGwb3y= NYD0O5ZQcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl MX:yN|AzQDhyMx?=
HEC-1A MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr0NVAxKG6P M332WVI1KGh? M1rmT4V1cGGwb3y= Mn7abY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln MYOyN|AzQDhyMx?=
NHAC-kn NWfCT21DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNE8yODBxNUCwJI5O MWSxNkBp MWPEUXNQ NFSzS5hKSzVyIH;mJFUxOG6P NEP6ZW0zOzBzN{i3NS=>
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3flNlI2OCCwTR?= MmHROk04OiCq MXzEUXNQ NHfOU2Nk[XW|ZYOgZUBoemWjdHXyJIlvcGmkaYTvdpkh\W[oZXP0JINwdWKrbnWge4l1cCCWWGSgc5Ih\XKub4Tpcolj NVjkVlU6OjJ7OUS3PFA>
MG-63 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXCd4tZOzByIH7N NYDGcGJCOTJiaB?= MUjEUXNQ MoHQbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MlLDNlI4QTl|M{i=
MG-63 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVztO|E2OzByIH7N NHW2WIozPCCq MYnEUXNQ NVXMTWM3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= MoT0NlI4QTl|M{i=
MG-63 NGf3UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnEcoQ4OzByIH7N NYPqco5IPDhiaB?= MV7EUXNQ M3nNdIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? Moe5NlI4QTl|M{i=
HL60  NGjNeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxOVAuOzVyIH7N MWqyOEBp NGrnSVdqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O MXuyNlc2Ozd|OR?=
U937 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml74NVUxNTN3MDDuUS=> MoLiNlQhcA>? NVP4b|BCcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? MmTPNlI4PTN5M{m=
SCC-6 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfrXo4zODBvM{KwNEBvVQ>? M173fFEzNzJ2L{S4JIg> NWPKe5dLTE2VTx?= MontbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M3;HbVIzPTV{M{Kx
U87  NYjxRoZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\oU|ExOC1|MECgcoc> Ml3YNlQhcA>? NVrMXWRtcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= NIW0OIYzOjJ5MEi0PS=>
K562 M363fmZ2dmO2aX;uJGF{e2G7 NX\ocJNNOSEQvF2= NWjPT5VwOTJiaB?= M2X1cGROW09? MULlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MVqyNlE4QTF7OB?=
Reh NVHIW3djTnWwY4Tpc44hSXO|YYm= NH;US5AxNjNxMTFOwG0> MknwNVIhcA>? M3\EUGROW09? MkLV[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MmKzNlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03185429 Not yet recruiting Tumor Gastric|Tumor Colorectal BGI China|Fujian Cancer Hospital December 2017 Not Applicable
NCT02959905 Recruiting Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT02695758 Completed Osteoarthritis: Shoulder Rothman Institute Orthopaedics December 2014 Not Applicable
NCT00158418 Completed Osteoarthritis Fowler Kennedy Sport Medicine Clinic|Zimmer Biomet August 2002 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID